FIGS, Inc. (FIGS) Earnings Call Transcript & Summary

November 5, 2026

New York Stock Exchange US Consumer Discretionary Textiles, Apparel and Luxury Goods earnings 64 min

Earnings Call Speaker Segments

Tom Shaw

executive
#1

Good afternoon, and thanks for being with us to go over FIGS' third quarter 2026 results. We put those out this afternoon, and you can find them in our earnings press release as well as in the shareholder presentation that's posted on our investor relations website at ir.wearfigs.com. On today's call, we have Trina Spear, our Co-Founder and Chief Executive Officer, and Sarah Oughtred, our Chief Financial Officer. Just as a reminder, anything we say on this call that isn't about past events counts as a forward-looking statement. That can cover predictions, expectations, or estimates, including ones about future financial performance, market opportunity, or business plans. Forward-looking statements carry risks and uncertainties, and actual results could differ materially. Those risks and others are discussed in our SEC filings, including in the 10-Q we filed today. Please don't place undue reliance on forward-looking statements, since they speak only as of today and we undertake no obligation to update them. Last, we'll be discussing certain non-GAAP metrics and key performance indicators, which we believe are useful supplemental measures for understanding our business. Definitions and reconciliations of these non-GAAP measures to their most comparable GAAP measures are included in our shareholder presentation. With that, I'd like to turn this call over to Trina.

Trina Spear

executive
#2

Thanks, Tom. Good afternoon, everyone, and thank you for joining us. FIGS delivered another exceptional quarter, surpassing expectations on both revenue and profitability. Net revenues climbed 26% to approximately $191 million, well above our 20% guidance and representing our fourth straight quarter with growth exceeding 25%. As before, the momentum was widespread across categories, channels, and geographies. Our customer metrics showed accelerating year-over-year gains in three key areas: active customers grew 14% to almost 3.2 million, average order value increased 11% to $126, and net revenues per active customer rose 13% to a new FIGS record of $236. On top of the strong top-line results, we also improved profitability even with costs elevated across the board. Adjusted EBITDA margin came in at 16.5%, which is 410 basis points higher than a year ago and above the roughly 14% we had guided to. Gross margin stayed remarkably robust at more than 69%, and SG&A leverage came in better than we had planned — another sign of how powerful our model is as we scale. We keep deploying capital, buying back about $14 million of our shares in the period, on top of the extra $100 million authorization we announced in August. That makes four outstanding quarters in a row. Throughout that stretch, the question we keep hearing is how we are producing such a sharp inflection in the business. To put it simply, this resulted from a mix of excellent products, deeply resonant marketing efforts, a community we feel very close to, and solid industry basics. That simple framing doesn't capture the full picture. Pulling all of it off was hard work. It demanded a major leap forward in many areas where we'd already been doing well, yet we recognized the need to improve further. Central to this effort is the outstanding team we've built over the last few years, with capable leaders lending support to strengthen what we do in product, marketing, supply chain, finance, international, TEAMS, and community hubs. The work and passion of these people have been essential to bringing out this compelling narrative that was present the whole time. When it comes to product, our core offerings have always defined the category. What's different now is the level of sophistication we've brought to every element of our go-to-market strategy, and that really started gaining traction during the latter half of 2025. Today we're more in sync than we've ever been when it comes to how we interpret and set style, how we execute impactful color, how we refine fit, how we broaden our fabric range, how we strengthen merchandising, and how we commit inventory to both core and limited edition; on the brand side, we sharpened our attention on the upper part of the funnel, with last year's Where Do You Wear FIGS? serving as the anchor. We ran that campaign and are carrying it into this year with Never Change; we made the most of big viral moments, from the Olympics to Noah Wyle at the Emmys, amplified our community backing through broader advocacy, and brought more sophistication to every stage of the funnel. That combined effect is real and distinguishes us, and we supported these efforts in product and brand to serve a sector that is becoming less common in today's climate. On top of healthcare apparel being a replenishment category and essential, the jobs picture is strong, with healthcare-related employment powering the economy. We expect that to remain the case far into the future. Actually, even with concerns that AI could shake things up, the Bureau of Labor Statistics projects that this field will create more positions than any other sector across the next ten years — approximately 37% of all newly added jobs. The work itself is inherently human, and we're proud to have cultivated a real community around it. We recognize that this industry is remarkably robust, yet achieving success depends on building genuine personal connections with the healthcare professionals who keep it going; we've seen a number of long-standing companies in the space struggle while we've accelerated, and we think our ability to propel product innovation, generate impact, and foster community ties is what puts us on a distinct path. Despite this stretch of strong results, our attention is on what comes next — keeping up our momentum and generating growth over the long term. Crucially, we view our recent work and success as foundational. They were never meant to be mere one-off wins, but instead durable building blocks that create lasting impact for healthcare professionals. Solid foundations allow for further progress, and we're aiming at a wide range of opportunities to raise once more the high bar we've set. For example, in product, our improved design capabilities are only now beginning to make a meaningful difference. Our inventory positioning and depth are poised to get better and become optimized. We're accelerating the expansion of our head-to-toe category, and that expands the TAM. Looking at how far our brand reaches, we are far from done when it comes to serving more of the more than 100 million people in the global healthcare community. Domestically, brand awareness remains relatively low, our digital experience has room to become more personalized and engaging, and omnichannel connectivity is still untapped. Outside the U.S., international makes up less than 20% of our total mix, and several key growth markets are still early. Physical, in-person access to our brand remains fairly limited, with just nine community hubs slated to be open by year's end. The TEAMS B2B opportunity to address institutional healthcare needs is still ahead of us. Additionally, regarding impact, our efforts to support those who support others continue without pause. That represents a true point of brand differentiation and something our community is owed, and we are sharply focused on scaling that impact as our channels and geographies grow. Combining our current momentum with these possibilities, we feel optimistic about our direction and about extending this unique growth narrative. Before I go further into product, brand, and market expansion, let me update you on our supply chain in light of the Jordan situation we discussed last quarter. Although the WRO is still in effect, we are progressing with our internal initiatives. Recently, my team and I went to Southeast Asia—partly to back the supplier relationships we already have in Vietnam, and partly to push our diversification work further. We’ve locked in extra capacity in Vietnam. Output is climbing, goods are moving faster, and inventory is getting better in real time. During Q4, we’re using our current partners to launch our first production lines at sites in Indonesia, and by the end of 2027 we expect that to support a more meaningful mix of our business. We’re pleased with the near-term progress, even though the overall strength of demand pushes some of our inventory replenishment work into Q1. Overall, everyone across the organization contributed—particularly given the condition of our vendor network just a year ago; at this point, let's examine a few of our product narratives and the areas where results are showing up. The business's continued turning point keeps demonstrating increasing refinement in the way we bring merchandise and complete head-to-toe offerings to the market. At the same time, our people are showing the toughness needed to make significant short-term shifts to our schedule, allowing us to lessen the effects of vendor interruptions; during Q3 we introduced multiple impactful color ranges, which generated notable buzz on their debut dates.

Trina Spear

executive
#3

The quarter's gains were widespread, spanning our Spider-Man partnership, the back-to-school season, a limited Espresso release, Breast Cancer Awareness, and additional initiatives. Our newly launched durable FibriX fabric performed better than we had anticipated, drawing strongly favorable social sentiment, with customers highlighting in particular our streetwear-inspired styling, the durable structured silhouette, and the overall design. On the design front, we keep setting our scrub pants apart through fresh waistband options rolled out across a number of our top-selling styles; following our recent purchase of Ecodear, we widened our non-scrubwear opportunity via a dedicated collection of jewelry, pins, charms, and accessories made specifically for healthcare professionals; that product made its official debut in August under the name Charmacy, forming a natural extension of the uniform by blending emotional engagement, personalization, and collectibility. As we noted before, a large share of the initial launch sold out, and we built a wait list of almost 10,000 healthcare professionals while we work to restock the assortment in time for the holidays. Q4 is off to a quick start thanks to our fall drop, which features the full return of Espresso, our most requested color. That launch also demonstrated our unmatched innovation flywheel, as we introduced new fabric and style within our boucle outerwear assortment. During the past few weeks, we have also begun to improve our position from an inventory standpoint, including in our core Rafaela and Kade styles, and that process will carry on over the coming months as we build up supply and pursue strong demand. We are eager to introduce more newness across our FibriX and FORMx fabrications, along with our popular bag lines. Our brand's reach has never been wider or more impactful. Impact trips remain a defining part of our work to change healthcare. On these trips, we journey around the world alongside our FIGS ambassadors to deliver support for a wide variety of healthcare needs. In July, together with Operation Walk Los Angeles and St. Elizabeth's Hospital, we sent a team to the Philippines that provided more than 40 free joint replacements. We recently carried on our efforts in Kenya at the FIGS Operating Theatre, the state-of-the-art hospital center we built in 2024. So far, this remarkable facility has enabled over 2,500 surgeries that this community of 500,000 Kenyans would otherwise have gone without. Moving from advocacy to education, last month we introduced a dedicated FIGS moment with Augmedix, the AI-powered multidisciplinary education platform for healthcare professionals that aims to redefine a broken continuing education industry and process. We invested in Aug two years ago because we saw this opportunity fitting with our overall mission and greatly expanding the ways we can serve healthcare professionals. We have also now signed a collaboration agreement with Aug that gives FIGS a range of benefits, among them marketing, data, and AI. Beyond all these efforts that are uniquely FIGS, we have our major brand moments, and this week we are going big with the final chapter of our year-long Never Change campaign. This serves as a strong closing note for our 2026 work, meant to highlight all the positive things that exist in healthcare. It's one more illustration of what will stay constant throughout the community we feel so privileged to serve. Last, I'd be remiss if I didn't give a shout-out to our brand partner and friend, Noah Wyle, whom People magazine has just named the Sexiest Man Alive for 2026. To celebrate our community, we teamed up with People to demonstrate that sexy people save lives, shining a fun spotlight on six of our FIGS ambassadors within the broader feature. Moving to market expansion, beginning with international: third quarter net revenue growth jumped 51% as our international mix nears 20% of total business. Our broad-based strength stood out in particular across Latin America, Mexico, the Middle East, and Europe, where the payoff from greater localization and community-building efforts is coming through. All told, we're excited about both strong traffic gains and remarkable growth in our baseline days internationally, which we view as yet another healthy indicator of sustainable demand; in TEAMS, we're demonstrating our strategy for building a pipeline of larger opportunities. For instance, we're rolling out our recent partnerships with Bupa Dental Care, which has nearly 400 dental centers in the UK, and European Wax Center, which has just over 1,000 aesthetics locations across the US. We see these partnerships as blueprints for serving larger businesses in higher education, especially as we keep building solutions that simplify order complexity for a broader range of institutions. On the community hubs side, we posted another quarter of double-digit comp store growth, with non-comp performance beating our expectations. All four of our 2026 openings are slated for later this year: Tysons Corner in the Washington, D.C. area, Fashion Square in Scottsdale, Aventura Mall in Miami, and Valley Fair near San Jose. We're continuing to advance our real estate pipeline and expect a larger, more balanced store opening cadence in 2027. Importantly, the proof points remain compelling: a higher mix of new customers, a payback well under our two-year target, and accretive margins. In summary, our continued outperformance puts us on pace for our fastest full-year growth since the hypergrowth performance of 2021, when we were just about half the size we are today. It's been a landmark year for FIGS, and I'm extremely proud of our ongoing execution and improving performance, even amid the noise of the macro, global uncertainty, and trade disruptions. As we focus on stepping into the new future, we're set up to grow Q4 in the mid-teens range on top of our blockbuster 33% growth in Q4 last year, accelerating our two-year stacked performance to nearly 50%. That's a powerful statement to exit the year. Along with top line, we're firmly focused on driving our adjusted EBITDA margin even higher. While we won't sacrifice investments to support the long-term aspirations of our brand, we do expect our discipline around profitability to continue in 2027. Healthcare professionals sit at the heart of everything we do. The needs they serve aren't going to change, and our dedication to being there for them won't change either. With that said, I'll hand things over to Sarah so she can take you through the financial results and our outlook.

Sarah Oughtred

executive
#4

Thank you, Trina. FIGS delivered a strong third quarter, extending an amazing stretch of four straight quarters marked by heightened growth, improved profitability, and a strengthened balance sheet. First, I'll cover the specifics of our broad-based Q3 results, and then I'll discuss why we're increasingly confident about bringing that momentum into Q4, supported by our lifted full-year guidance. Turning to Q3 specifics: net revenues rose 26% versus a year ago, reaching $190.7 million, which beat our guidance that had anticipated roughly 20% growth. Our strength remained notable in its breadth—spanning scrubwear and non-scrubwear, within the US and internationally, and across all our sales channels. Color launches made a particularly strong impact this period, and that was paired with the steady success of our routine selling days that had no dedicated brand or product activations. As we expected, stockouts tied to our Jordan supplier transitions affected part of the back half of the quarter. Growth in active customers sped up for a fourth consecutive quarter, rising 14% from a year earlier to nearly 3.2 million, backed by a healthy mix of new and returning shoppers. Average order value climbed 11% to $126, with even contributions from a higher average unit retail and better quality of sales. The AUR improvement came from both our early 2026 pricing move and product mix, while quality of sales benefited from reduced discount and return rates. We also took encouragement from the ongoing decline in the number of days between purchases among our returning customers. Combined, these factors pushed our trailing 12-month net revenues per active customer metric up 13% to $236, another FIGS record. Looking at category, scrubwear rose 24% and accounted for 83% of net revenues in the period. Core styles stayed robust, fueling demand all quarter, while the range and impact of limited edition colors plus expanded FibriX styles produced strong sell-through and enthusiasm. Non-scrubwear climbed 35%, making up 17% of net revenues, the same broad-based growth with balanced share across categories. Underscrubs benefited from momentum in our core franchises and appetite for new limited edition offerings. Outerwear was driven by core scrub jackets and fleece, reinforcing our category optimism ahead of expansion efforts in Q4. Footwear's strength came from strong color coordination and new styles. Accessories featured the debut jewelry assortment from the Charmacy, offering yet another fantastic way to build and personalize the uniform from head to toe. Geographically, US net revenues grew 21% to $153.9 million, while international net revenues jumped 51% to $36.8 million. In the US, we entered the quarter with solid momentum and encouraging leading indicators, and we leave the period with that same favorable setup. That includes continued strong gains in site traffic, social followers, search trends, and email and SMS subscriptions. Compared with historical cohorts, new customers are arriving with higher AOV, beyond just the effect of pricing, and they keep that relative strength as they return to the brand. Among returning customer cohorts, order frequency and spend are also on the rise. We see these signals of improving customer quality across our active base as powerful foundations for future growth. International growth keeps showing a healthy mix of new and returning customers. Trina pointed to especially notable gains in Latin America, Mexico, the Middle East, and Europe, and we were likewise happy to see solid growth throughout the rest of the world. We've added 27 markets so far this year, bringing the total to 85, yet close to 90% of Q3's total international growth still came from our existing comp markets. Q3 gross margin narrowed 60 basis points to 69.3%, which was still ahead of what we expected and remains quite strong. Keep in mind that the comparable period last year got a favorable boost from our returns-processing improvements, which drove outsized performance that period. Higher inventory reserves were another headwind, but we kept seeing positive effects from pricing and efficiency work, including costing, more full-price selling, and lower return rates. Selling expense came to $44.4 million in Q3, or 23.3% of net revenues, versus 23.6% a year ago. That lower expense rate was mainly the result of net revenue leverage. Our continuing progress on outbound carrier optimization and fulfillment efficiencies has also helped counter persistent fuel pressures, our supplier transitions, and the impact of international mix. Marketing expense in Q3 was $25.5 million, or 13.4% of net revenues, down from 15.5% last year. Q3 performance reflected both net revenue leverage and digital marketing efficiencies. Those gains keep providing strong support for building international brand awareness and other brand-enhancing partnerships. G&A was $40 million in Q3, or 21% of net revenues, versus 24.5% last year. That lower G&A rate stemmed mainly from net revenue leverage, partly offset by investments in our team. Q3 operating margin rose 520 basis points to 11.6%, up from 6.4% last year, while adjusted EBITDA margin improved 410 basis points to 16.5%, versus 12.4% last year. As a reminder, adjusted EBITDA margin for Q3 and year-to-date includes only the tariff refund portion tied to goods sold in those periods, with no benefits related to fiscal 2025. Net income for the quarter was $19.3 million, or diluted EPS of $0.10, versus net income of $8.7 million last year, or diluted EPS of $0.05. On the balance sheet, we ended the quarter with record cash, cash equivalents, and short-term investments of $331.2 million, roughly 10% above our previous peak in Q4 2025. That marked a 37% year-over-year increase, even after we allocated about $60 million across the nine-month period to share repurchases and moved to net share settlement of employee equity awards. Inventory fell 20% year-over-year to $121.3 million, driven largely by the combined effect of our supplier transitions, strong sales, and continued optimization work. We expect inventory to stay down year-over-year in Q4 before it starts rebuilding in 2027. Share repurchases in the quarter under our ongoing program came to roughly $14 million at a weighted average price of $14.02 per share. Counting the previously announced $100 million boost to our authorization, we had roughly $105 million left for future buybacks under the program at quarter end. Last, capital expenditures came to $5.7 million for the quarter, which reflected software capitalization, leasehold improvements, and spending tied to community hubs for our Q4 openings. Moving now to our updated outlook: we've raised Q4 expectations for net revenues and now anticipate year-over-year growth of approximately 15% for the period. Along with the fundamental strength of our Q3 results, we now project full-year 2026 net revenue growth of roughly 23.5% year-over-year. That exceeds our earlier full-year guidance of approximately 20% growth and is about twice the top end of the original outlook we gave on our February 2026 earnings call; in our view, the growth and behavior of our active customer base are strong signals of demand, backing the robust start to the fourth quarter, which featured an extremely successful fall drop in October and early gains in our core in-stock levels. At the same time, we're aware that a meaningful portion of the quarter still lies ahead, where we're comping last year's exceptional strength and execution.

Sarah Oughtred

executive
#5

Given how strong demand has been through this year, we believe there could have been even more room to grow if we hadn't run into limited-edition stockouts during the near term. Even with that, the two-year stack of approximately 50% implied for Q4 shows just how much momentum our business has. On margins, we now expect full-year GAAP gross margin to come in around 69.9%, up from our prior outlook of roughly 69.5%. That number, as we said last quarter, reflects the $15.4 million cut to cost of goods from the tariff refund booked in Q2, an additional $1.9 million benefit in Q3 as those affected goods sold during the quarter, and what we expect for sell-through of the related inventory in Q4. Although those refund-related expectations remain unchanged, the underlying gross margin expectations have improved thanks to strong full-price selling, a more favorable product mix, and lower air freight than we had planned; for Q4, we expect a sizable improvement year over year, partly because of the large inventory write-off comparison from the year-ago period. Within SG&A, we'd flag two factors for Q4 expectations. First, we anticipate a higher selling expense rate year over year, driven by supplier transition costs and continued pressure on outbound freight. Second, we anticipate a lower marketing expense rate year over year, driven by our ongoing efficiency efforts and the comparison to last year's ramp in Winter Olympics investments. All in all, we've lifted our full-year operating margin guidance to roughly 12%, compared with the approximately 10.8% we had projected before; in addition, we've increased our full-year adjusted EBITDA margin target to around 15.8%, which is above our prior range of 14.8% to 15%. We're positioned to close out a strong year in strong fashion. For the full year, net revenue growth is expected to be the best we've seen since 2021. Adjusted EBITDA margins are expected to swing up 650 basis points from their low point in 2024, and our balance sheet is the strongest it has ever been. Equally significant, we're set up to carry that momentum forward on revenue and earnings alike through 2027; at this point we're glad to take your questions. Operator?

Adrienne Yih

analyst
#6

Great, and thanks so much. Congrats to the entire team, everyone, on superb execution. Trina, I suppose my first question is that you've sort of reached a new high-water mark, correct? The last four quarters in a row have all come in above 25%, and even as you lap a really, really robust fourth quarter from last year, you're still guiding to 15%. The year is winding down, and as we think ahead toward 2027, it sounds like there are so many additional avenues of secular growth open to you, not least of all what you just mentioned regarding longstanding healthcare employment. Could you talk about how we should think about possibly a new algorithm for the company? And then second, for Sarah, could you speak to the competitive share opportunity — Scrubs & Beyond is clearly shutting its US brick-and-mortar stores, so what size opportunity is that, and apart from you, who else do you see moving in to take that competitive white space now? Thank you.

Trina Spear

executive
#7

Thanks a lot, Adrienne, for that question. I'd say it's a thrilling time at FIGS. What you saw this quarter is growth that's remarkably broad-based — across category, across channel, and every growth area we're concentrating on, ranging from our international business to TEAMS to our community hubs. To give you a picture: the US was up 21%, international rose 51%, scrubwear gained 24%, and non-scrubwear climbed 35%, while hubs and TEAMS came in ahead of what we expected. We feel really good about our position and how we're set up as we head into 2027. Everything is running on all cylinders — from the product side, where we're delivering new fabrications and new functionality to the healthcare community, to our marketing campaigns, which are genuinely connecting across the board. And that's happening despite a supply shortage, right? Demand right now is far outstripping supply. We feel really good about how we're set up, particularly as we move into an even better inventory position going into 27. We're ready. We can hardly wait to grow, and we're ready to keep scaling, ramping up, and performing at the top level. When it comes to competition, we genuinely see ourselves as our own rival. Our entire focus is on the healthcare community, and that community is just as focused on us. I believe you brought up one of the established players, Scrubs & Beyond, closing and winding down over 100 locations. Our plan is to keep taking market share and to keep expanding TAM. No brand in this market compares to FIGS, and none is as devoted and fiercely dedicated to our customer, the healthcare professional. The only rival we've ever had is us, and that won't change going forward.

Adrienne Yih

analyst
#8

Great. Sarah, just a couple of housekeeping items—well, maybe not really housekeeping. When should we start to see the effect of Jordan sort of no longer affecting our ability to kind of capture sales? Then just remind us, what's the strategy when it comes to kind of offsetting share creep with diluted shares kind of over time? Thank you. Sure. I think,

Trina Spear

executive
#9

in Q4, the WRO Jordan situation will hit us the hardest. We'll see some impact all the way through Q2 of next year, but the worst of it comes in Q4, and that is built into the guide.

Sarah Oughtred

executive
#10

Regarding the share repurchase program, we've done an excellent job this year putting cash to work there. We've completed more than $40 million in buybacks and have also directed cash toward net settling, $60 million for the year-to-date. So far this year, we've already repurchased and offset all of the dilution, so our aim going forward is to keep managing dilution through those buybacks. We also maintain a very strong balance sheet, which lets us stay opportunistic and identify the right chances to return value to shareholders and manage share count.

Adrienne Yih

analyst
#11

Great. Thank you. Great job.

Trina Spear

executive
#12

Thanks, Adrienne.

Matt Koranda

analyst
#13

Hi, everyone. Great work. I was hoping to dig a little deeper into those new customer cohorts you mentioned during the prepared remarks. It sounds like they're coming in with higher average order values. I just wanted you to break down what you believe is behind that. Is it a different kind of customer profile on the healthcare side? Is it new marketing channels, perhaps? Or is it simply a broader assortment that's now available to them? Maybe just walk us through that a bit.

Trina Spear

executive
#14

Absolutely. When it comes to the healthcare professionals we've brought in, each cohort has arrived with greater value and more strength than the ones before it. That's a wonderful signal, isn't it? It's a strong leading indicator of what lies ahead and of how we'll maintain the momentum we had in the third quarter and are seeing in the fourth quarter; we're truly excited. Part of this, I believe, stems from the industry environment and emerging from the COVID overhang as the industry normalizes. What I'd say is that in terms of repeat frequency, we aren't even back to pre-COVID levels yet; the cohort data we're seeing is really encouraging, but we think there's a great deal more we can accomplish — not only because of the industry, but also because of what we're doing throughout our layering system, how we engage our community, not just in our scrubwear but across categories, from our underscrubs, our outerwear, our compression socks, our footwear collab with New Balance — so much, much more to do and much more to come, but we're definitely seeing incredible data in the cohorts.

Matt Koranda

analyst
#15

All right. Moving to my follow-up, I was wondering whether you can give — or are able to give — some indication of the headwind you saw from stockouts? I realize supply has been somewhat difficult to secure over the last few months, so is there any way to put a number on what the growth might have been with a more typical supply flow? And then perhaps for Sarah, how does inventory get rebuilt, and what level should we regard as more normalized when thinking about next year?

Sarah Oughtred

executive
#16

Certainly; revenue for the quarter came in at $190 million. That represented 26% growth. It exceeded what we expected; our guidance had been 20, since we knew inventory supply would pose a problem for us, yet we outperformed, which was great; we still believe more would have been possible in a more optimal position. Perfectly quantifying that is really difficult, but I think one could assume we would be nearer in revenue volume and growth levels to what we saw in Q2. That will serve as a tailwind as we consider growth opportunities for 2027; we have taken quite a few steps to try to bring that inventory supply in faster. We have air freight that we've invested in through the P&L to help improve that. We have been seeing improvements in core during the quarter to date, but what happened is that the Q3 outperformance, really driven by limited edition, has constrained our limited edition supply into Q4. All of that is reflected in the Q4 guide, but we do feel we are continuing to improve that position each and every day. We think there will be some impact into Q1, but we're working as quickly as possible to improve that inventory supply so we can keep up with the amazing demand that we're seeing.

Trina Spear

executive
#17

Matt, here's another data point on that. Traffic to our site has risen by mid-30s percent, so you can compare that figure against the sales we recorded in Q3 and the guidance we gave for Q4.

Matt Koranda

analyst
#18

All right, that's been really useful. I'll stop there. Thank you.

Brooke Roach

analyst
#19

Good afternoon, and thanks for taking our question. Trina, for the past several quarters this business has been posting some very strong growth rates above 20% in the domestic channel. As you move into '27 and past that, how do you think about a more normalized run rate, or a sustainable pace of growth in demand for the US business? How are you framing that in terms of new versus existing customers, relative to other growth initiatives like community hubs and the TEAMS business?

Trina Spear

executive
#20

Thanks, Brooke. The US is genuinely what's driving the business today and what will keep driving it; we've now posted four consecutive quarters of 20%-plus growth in the United States. Most of that is coming from our core e-commerce channel. That's why it was so exciting, because we view that as a continuing growth lever, but there's much, much more to come as we open four additional hubs this quarter in our hubs business, and TEAMS is really beating expectations too. We're truly excited to see this success and this momentum. Looking ahead to 2027, if you consider the leading indicators, we've discussed this before, but search is up considerably, double digits year-over-year, and FIGS keeps outpacing searches for scrubs. Traffic is up, as I mentioned, in the mid-30s. Our social following is up nearly 40% year-over-year with even stronger engagement and interest. Email lists, subscriber lists, SMS — email and SMS are up 30%-plus. All these leading indicators give us plenty of confidence heading into 2027 that we'll keep engaging our community. In healthcare jobs over the next 10 years, I believe we said this in the prepared remarks, 37% of new jobs over the next 10 years will be healthcare jobs. Over the past year, more healthcare jobs have been created than in the overall economy. We have a tailwind from the healthcare backdrop, and then really seeing these leading indicators gives us a lot of confidence in where we're headed, and we couldn't be more excited about how we're positioned and how we'll keep executing.

Brooke Roach

analyst
#21

Great. Then just one follow-up for Sarah. Could you lay out the key levers behind further operating profit margin expansion past the 12% rate you're on track to hit this year? Do you see a ceiling to that level in the near or medium term, and how should we think about the upside?

Sarah Oughtred

executive
#22

Sure. We've witnessed the effects of our higher revenue, which has generated considerable leverage flowing through to the bottom line; on top of that, we've put substantial effort into identifying efficiencies within the P&L, and you're seeing that keep delivering excellent results too. When we consider some of those opportunities, they lie in the higher quality of sales we're delivering, lower discounts, improvements in returns. Returns are in fact the lowest they've ever been historically for the company, so that's been really great to see. Looking at our selling costs, we've kept working on various different strategies to optimize cost per orders while also improving that customer experience; we've seen great efficiency within marketing from the efforts we've been doing to invest in the upper funnel, and we're really seeing traction from all of our investments there. We continue to see that there will be opportunity into the future from both of those; we still have work to do to continue to improve those efficiencies. With the growth we are expecting, we will have that produce higher results for operating margin not only into next year, but over the next several years as well.

Brooke Roach

analyst
#23

Many thanks. I'll be sure to share that.

Brian Nagel

analyst
#24

Hello there. Good evening to you. What a strong quarter. Congratulations on it.

Trina Spear

executive
#25

Thank you, Brian.

Brian Nagel

analyst
#26

So the question I'd like to ask is probably aimed more at Sarah, and I think you touched on this somewhat in your prepared remarks, but I'd like to go a bit deeper. The performance has been great, and there's clearly momentum behind the business. What's giving you confidence? You raised the fourth-quarter sales guidance a bit here. You've got that tough comparison. Looking at the business now, what makes you confident you can hit that kind of sales growth on top of the sales growth you've laid out here, and on top of that really difficult comparison?

Sarah Oughtred

executive
#27

Sure. Yeah. We're off to a really great start in Q4, but we also recognize Q4 is heavily back-weighted, so we're being prudent. We're coming into the quarter with really strong growth in our active customer base, right? We've been seeing that active customer base keep accelerating in growth, and that's really going to help us with momentum into Q4, as well as into 2027. We've seen our AOV continue to improve, and we're seeing nice trends in frequency. Add to that what we're seeing in terms of all the leading indicators we continue to monitor, which includes our Google search interest, our email subscribes, our SMS subscribes, and what we're tracking in terms of our brand awareness. Those are all showing really great signs, and we do have confidence in continuing to be able to deliver despite some of the inventory challenges we currently have.

Brian Nagel

analyst
#28

That's useful. And then, on Q4 as well — sorry for keeping things so short-term here — but from what you said, it sounds like you're actually nudging up your gross margin guidance for the fourth quarter a bit. First, did I get that right, and second, what's kind of the reasoning behind it?

Sarah Oughtred

executive
#29

Sure. Yeah. Q3 gross margin came in better than we expected, and that really came from favorable product mix plus our improvements in discounts as well. We're taking that expectation forward into a higher Q4 gross margin outlook too.

Brian Nagel

analyst
#30

Understood. Thanks a lot, and congratulations once more.

Sarah Oughtred

executive
#31

Thanks.

Trina Spear

executive
#32

Thank you, Brian.

Dana Telsey

analyst
#33

Hey, everyone. Congratulations on the momentum you've been building — it's genuinely exciting to see. I've got two things. First, on the top line and just how robust active customers are. I think another move you're making is bringing in categories — I really like the Charmacy name and what you've built there. How do you view the ability to keep growing the top line through further product extensions or additional categories? And second, just a small refinement on gross margin. I believe you mentioned some improvement in returns processing. How much did that add to gross margin, and is there more upside ahead? Thanks.

Trina Spear

executive
#34

Perhaps I'll begin. Thanks a lot, Dana. Our goal is really to keep the momentum going throughout the company and in every category. We're very excited about Charmacy—appreciate you mentioning it. It genuinely offers our community a way to make their uniforms personal, and it's a lot of fun. It spans pins, jewelry, and charms, and we're just thrilled about what lies ahead. Our team is bursting with ideas and innovation on that front, and there's plenty more coming. On top of that, we're bringing FIGS Pro back next year. There are several partnerships in the works that we're really enthusiastic about — along the lines of the Spider-Man project we recently completed. We've developed fresh fabrications along with added functionality throughout the layering system, and that combination will address a growing share of what healthcare professionals require. Sarah, would you like to pick up the rest?

Sarah Oughtred

executive
#35

Returns handling has been a priority for us for over a year at this point, and the outcomes have been quite impressive. It's helping drive revenue growth and adding to the positive trend in gross margin. We've had many initiatives underway, but I'd say one of the key ones is our fit — that was an area where we received feedback and put a lot of effort into throughout last year, and we're now seeing significantly reduced return rates on our new fits; it confirms the approach is paying off and that our customer is more pleased with our fit and with what we're able to offer. Beyond that, we've had additional initiatives underway aimed at making returns and exchanges simpler for customers, and there remains room for further improvement. It's certainly delivered gains, and we expect that to remain an opportunity as we move through Q4 and on into 2027.

Dana Telsey

analyst
#36

Thanks.

Bob Drbul

analyst
#37

Hello, good afternoon. I've got a couple of questions, if that's alright. First, considering how well your marketing campaigns have done, how do you go about topping what you're already doing? Especially as you think about the opportunities out there with the capital and investments you've put in. Then my second question would be about the international markets—with some of the newer ones you've moved into, could you speak to those, what you've learned, and where you see opportunity today? Thanks.

Trina Spear

executive
#38

Thanks, Bob. No, I'd say we're only getting started, and there's always more work to be done. On the marketing side, what you've witnessed these last few years is that we've surfaced just unbelievably powerful campaigns and experiences and viral moments that have united the healthcare community, made sure they know we understand them, that we've got their back, and that we get them on a deep level. That effort never ends, right? The effort to genuinely understand the community—they're always evolving, always shifting, right? We have to be right there in lockstep with them, comprehending them deeply so we can keep showing what their experience is like and what they're made of; we have an amazing team that continually brings creativity and passion, and is truly inspired by this community, so that we can keep doing that. The healthcare community is quite remarkable and they inspire us daily, and that's really what keeps us going. On the digital side, I think we've grown far more sophisticated throughout the funnel and are really putting more and more into the top line. Only the finest brands globally can pull that off, right? Which is to take the gains you get at the bottom of the funnel, take those CAC gains, and plow them back into the top of the funnel. You're seeing that with our billboards in Times Square, right? That's the kind of true top-of-funnel marketing we aim for. We're genuinely adopting a more integrated approach and integrated planning across our product, our marketing, our e-commerce, bringing products and stories to light in ways that are more differentiated and more coordinated, and that's really, really exciting; then at the bottom of the funnel, simply getting much stronger across the funnel, much stronger when it comes to measurement and execution. There's much, much more to do, but I do believe we've built a really strong engine, and it's genuinely part of our secret sauce, which is awesome. As for new markets, I'm really excited about what we're doing in Asia, and specifically Japan and Korea and China. We're only in the early stages of how we'll keep reaching more and more healthcare professionals around the world. Asia is still very much untapped, and there's a great deal for us to do when it comes to localizing in those markets—not only from a marketing perspective but from a product perspective too, really grasping their needs at a deep level and showing, in a personalized way, what makes sense for them across a range of use cases. Since people get enthusiastic about new markets, I'll note that 90% of the growth in the quarter still came from our existing markets—that's simply to illustrate it isn't just adding that's driving this growth; as for the future and what a lot of these markets will do, the sky's the limit, and we couldn't be more excited.

Bob Drbul

analyst
#39

Great. Thanks a lot. Congratulations. Best of luck.

Trina Spear

executive
#40

Thank you, Bob.

Rick Patel

analyst
#41

Hi there, good afternoon, and congratulations on the impressive progress. I wanted to ask about the TEAMS business. You're achieving a great deal with institutional customers. Could you give us an update on how large you expect this business to get by year-end? In light of the investments you've put in here, how big could it ultimately grow when we consider international markets and other areas?

Trina Spear

executive
#42

The TEAMS business is genuinely exciting. I believe we've come a long way with our technology. Our new TEAMS store has launched strongly, and we've truly built a platform that is far more seamless and far more self-serve. Our new TEAMS store launched in March, and throughout this year we've kept iterating and layering in additional functionality. We're also working with bigger institutions that adopt parts of the self-serve product yet still want guidance and concierge-level assistance — and we offer that as well. Running these large institutions — among the biggest we've ever had in our history — involves multiple locations and separate departments, so there's simply greater complexity. We believe we're learning a lot, and we're genuinely looking to support them in an expanding range of ways. It's an exciting time. We mentioned Bupa, and we mentioned European Wax Center. Big organizations are coming to FIGS so we can help them bring consistency, professionalism, and branding to their operations. That tells us a lot about our ability to work with concierge clinics, private practices, and additional kinds of healthcare institutions. Healthcare shows up everywhere — longevity, wellness, aesthetics. It keeps becoming a bigger part of daily life in more ways, and it keeps getting more consumer-driven. We sit right at the middle of helping shape where healthcare goes today, tomorrow, and far into the future. There are many more meaningful partnerships ahead that we'll tell you about soon. We aren't able to discuss them yet, but they're genuinely, genuinely exciting.

Rick Patel

analyst
#43

Great; one more thing I wanted to ask about was non-scrubs. Among the customers you have who buy scrubs today, how many of them are also purchasing non-scrubs right now? We've got the revenue numbers, but what I'd like to understand is attachment rates and whether this is a concentrated business, and how much of an opportunity engaging more of your existing customers could represent going forward.

Sarah Oughtred

executive
#44

It shifts somewhat from quarter to quarter because of seasonality, yet we're sitting in that mid-20s range for attachment rate, and penetration is climbing year over year owing to our push to broaden and provide some genuinely exciting options in non-scrubwear; we're aware that once a customer keeps buying more, building up cumulative purchases with FIGS, that's the point where they begin adding more non-scrubwear. The dynamics we're seeing are something we really like. We believe significant room for growth remains as we keep broadening our outerwear range, introduce additional fabrics in our underscrubs, and maintain the color strategy that has worked well for our footwear; this year we recently introduced compression socks, and Charmacy is the next exciting development that will bring in some of those elements—with your uniform, you want these non-scrubwear pieces to genuinely help personalize your look; we view that as an opportunity and expect to be really enthusiastic about everything that will keep contributing to that attachment rate going forward.

Rick Patel

analyst
#45

Thank you so much.

Nathan Feather

analyst
#46

Hey, everybody. It's genuinely exciting to witness the momentum we're seeing throughout the company. I'd like to dig a bit deeper into that TEAMS topic. Now that you've begun working with some bigger partners, which factors have mainly been the bottlenecks? You're attending meetings with folks who aren't buying at present. What do you still have to develop or introduce in order to serve them better? And given that you now have somewhat more data, how ought we to think about the sales timeline and cycle for that business, particularly when it comes to bigger clients versus smaller ones?

Trina Spear

executive
#47

Thank you, Nathan. My sense is that we're making progress. Nothing is holding us back from scaling that business further and continuing to onboard very, very large healthcare institutions. What I would say is that this year, we're pleased to see TEAMS growth bending upward and expanding faster than total revenues; it's an enormous opportunity as the healthcare sector, as I mentioned, grows more consumerized in order to engage in deeply meaningful ways. I genuinely believe the groundwork we've laid technologically has allowed us to scale far more quickly and to essentially sort institutions into two categories: are you aiming to self-serve, are you aiming to have every individual or every employee at your institution order on their own because you operate multiple locations or you want each person to receive their own uniform? That has been a massive unlock from the TEAMS standpoint. And from the concierge, larger-institution standpoint, we've genuinely developed plenty of technology that lets us serve them too, and offers stipend functionality, for instance. If you'd like an institution to spend $400 per employee a year and you want that available in their account, we now offer that capability, as one example. I truly believe there is far, far more ahead here, as I mentioned, a great deal in development, a great deal in the pipeline. As you pointed out, the sales cycle runs longer, yet I believe that with the process we've established, with the team we've assembled, we have an outstanding sales team, we've managed to shorten that sales cycle to a matter of months from potentially, in some instances, around a year. It's a truly exciting moment to leverage technology, leverage capabilities, leverage a team that's passionate and enthusiastic about this community in order to build incredible relationships that will pay dividends over the long term, considering the retention rates these institutions show with us, far higher than e-comm, and it's a genuinely excellent business and we're only just beginning.

Nathan Feather

analyst
#48

Really exciting. Thanks.

Ashley Owens

analyst
#49

Hello, great. Appreciate you taking our questions. Perhaps to begin, just to return to the international piece, that remark about 90% growth in existing markets. I know in the past you've discussed how some markets are hitting a tipping point where more awareness and word-of-mouth can lower that acquisition cost quite significantly. I'd just be interested to know whether you're beginning to see additional markets get to that stage, and is that starting to be reflected in those markets' profitability too?

Trina Spear

executive
#50

I believe our approach in international markets — going deep rather than going broad — has truly allowed us to invest suitably, given each market's size and scale, correct? Every market we're in is profitable, right? What's the reason? It's that we've been genuinely strategic about the way we invest throughout the funnel, the way we localize from one market to the next regarding our brand activations, regarding our e-commerce experience, regarding which channels we have. We're truly seeing amazing momentum particularly in markets such as Mexico, Latin America, the Middle East, and Europe. As I mentioned, earlier days in APAC have us very excited, and we're really excited about what that will bring going forward. Our focus isn't simply growing for growth's sake; this. We're genuinely aiming to do it with discipline and to concentrate on CAC and on what those investments will deliver over time. We feel really good about where we stand today and about how we'll keep driving engagement and awareness. Brand awareness remains so low across all these countries; we truly need people to know who FIGS is, because among healthcare professionals, there are 140 million around the world, and we have 3 million, 3.2. That leaves roughly 137 million healthcare professionals who don't know about us yet, so there's much, much more to do.

Ashley Owens

analyst
#51

Okay, got it. Perhaps just one last thing from me — when you look ahead to '27 regarding certain product costs, I'd be interested to know, as you begin placing orders for next year, what are you observing or picking up from suppliers about the underlying costs of products? And once you factor in items such as tariffs and, clearly, freight as well, do you believe the sourcing landscape is getting better or worse as we head into next year? Thanks.

Sarah Oughtred

executive
#52

Certainly. There are plenty of positives and negatives surrounding margin and our thinking on how 2027 will unfold, but beginning with the biggest item, the tariff refund, we received $15.4 million that boosted gross margin in Q2, and the rest of that refund went toward lowering inventory. As that inventory gets sold during Q3 and Q4, we are realizing further benefit there. We saw another $1.9 million of benefit in Q3 and anticipate more in Q4. Across all of 2026, the gross margin benefit comes to roughly 250 basis points, so that will act as a headwind on gross margin from a year-over-year standpoint simply because those tariff refunds were one-time in nature. Another factor affecting us is our move from Jordan into Vietnam — we have a somewhat different duty structure and are encountering somewhat higher costs right at the start with certain of our fabrications, which we can keep improving over time. Freight has affected our P&L both through inbound freight, which would impact our gross margin, and through outbound freight for the packages we ship out. At present, we are continuing to watch it. We aren't really planning for any decreases right now, but should we see a meaningful decrease, that could become a benefit into next year. As for gross margin, I'd say the normalized rate this year would be around 67.5%-ish, and I think we'll be roughly in that range next year given some of the positives and negatives.

Ashley Owens

analyst
#53

Great, I appreciate the added detail. Thank you, and good luck.

Sarah Oughtred

executive
#54

Thank you.

Trina Spear

executive
#55

Appreciate you all. One last point before we wrap up. Remember to pick up FIGS for every doctor, nurse, veterinarian, dentist, and all the healthcare professionals in your life. Wishing you a great holiday season. Talk to you on the next call.

Operator

operator
#56

This concludes today's call. Thank you for attending. You may now disconnect. Good bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete FIGS, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to FIGS, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in FIGS, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.